QPS ups capacity to support large-scale Ph III trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/alphaspirit)
(Image: iStock/alphaspirit)

Related tags: Contract research organization

QPS Holdings, LLC is investing in personnel and laboratory capacity for translational medicine at its headquarters in Delaware Technology Park.

According to the contract research organization (CRO), the expansion will enable it to process high sample volumes for Phase III clinical trials.

The investment is expected to result in a laboratory staff of 88, up from 57. The number of analysis teams will also increase from seven to 11.

Additionally, the CRO has created a working group to handle the demand for neutralizing antibody assays, according to QPS.

In line with the additions, the company has also expanded its dedicated immunobioanalysis and cell culture space, as well as the protein mass spectrometry area.

The company’s laboratories and testing facilities are located its headquarters in Newark, DE; Springfield, MO; Fargo, ND; Hollywood, FL; South Miami, FL, USA; Groningen, The Netherlands; Graz, Austria; Hyderabad, India; Barcelona, Spain; and Taipei, Taiwan.

Related topics: Preclinical Research, Phase III-IV

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more